Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G for Apellis Pharmaceuticals, Inc. Common Stock (APLS).
- Disclosed ownership: 7.7%.
- Date of event: 31 Dec 2024.
MORGAN STANLEY - 31 Dec 2024 SCHEDULE 13G Report for Apellis Pharmaceuticals, Inc. Common Stock (APLS)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- APLS
- Shares outstanding
- 124,581,182 shares
- Disclosed Ownership
- 9,592,751 shares
- Ownership
- 7.7%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Feb 2025, 13:09:31 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 7.7% ownership in Apellis Pharmaceuticals, Inc. Common Stock (APLS) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Feb 2025, 13:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 7.7% | 9,592,751 | 0 | 9,575,774 | Christopher O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley Capital Services LLC | 6.3% | 7,803,185 | 0 | 7,803,185 | Christopher O'Hara | Authorized Signatory, Morgan Stanley Capital Services LLC |